Impetigo - Pipeline Review, H2 2016

Summary


Impetigo is a highly contagious skin condition. Impetigo is caused by two bacteria streptococcus pyogenes and staphylococcus aureus. Symptoms include fluid-filled blisters, itchy rash, skin lesions and swollen lymph nodes. Risk factors include skin-to-skin contact, injury to the skin, having diabetes and having a compromised immune system. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Impetigo – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Impetigo (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Impetigo (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Impetigo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Impetigo.

Impetigo (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical
trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Impetigo (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Impetigo (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Impetigo (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Impetigo (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Impetigo (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Impetigo (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Impetigo (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Impetigo Overview 6
Therapeutics Development 7
Pipeline Products for Impetigo - Overview 7
Pipeline Products for Impetigo - Comparative Analysis 8
Impetigo - Therapeutics under Development by Companies 9
Impetigo - Therapeutics under Investigation by Universities/Institutes 10
Impetigo - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Impetigo - Products under Development by Companies 14
Impetigo - Products under Investigation by Universities/Institutes 15
Impetigo - Companies Involved in Therapeutics Development 16
Foamix Pharmaceuticals Ltd 16
Laboratories Ojer Pharma SL 17
Lytix Biopharma AS 18
Toyama Chemical Co Ltd 19
Impetigo - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
FMX-102 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
LTX-109 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
mupirocin - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ozenoxacin - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Synthetic Peptides for Infectious Disease - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Impetigo - Dormant Projects 36
Impetigo - Discontinued Products 37
Impetigo - Product Development Milestones 38
Featured News & Press Releases 38

Jul 12, 2016: Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
Jun 27, 2016: Medimetriks Pharmaceuticals New Drug Application for Ozenoxacin Cream, 1%
Accepted for Review by FDA
Jun 27, 2016: Medimetriks Pharmaceuticals Submits a New Drug Application to FDA for Ozenoxacin
Cream, 1%, a Novel Impetigo Treatment
Jun 12, 2014: Medimetriks Pharmaceuticals Announces that the Second Phase III Study for
Ozenoxacin has been Initiated by Ferrer
Jun 05, 2013: Ferrer Completes Phase III Clinical Trial Of Ozenoxacin In Adult And Pediatric Patients
With Impetigo
Feb 22, 2013: Lytix Biopharma Enrolls First Patient In LTX-109 Phase II Proof Of Concept Infection
Study
Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles
As Young As Two Months Of Age For New Antibacterial Compound Ozenoxacin
Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical
Treatment For Impetigo And Other Infectious Dermatological Conditions
List of Tables
Number of Products under Development for Impetigo, H2 2016 7
Number of Products under Development for Impetigo - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Impetigo - Pipeline by Foamix Pharmaceuticals Ltd, H2 2016 16
Impetigo - Pipeline by Laboratories Ojer Pharma SL, H2 2016 17
Impetigo - Pipeline by Lytix Biopharma AS, H2 2016 18
Impetigo - Pipeline by Toyama Chemical Co Ltd, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Impetigo - Dormant Projects, H2 2016 36
Impetigo - Discontinued Products, H2 2016 37

List of Figures
Number of Products under Development for Impetigo, H2 2016 7
Number of Products under Development for Impetigo - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Targets, H2 2016 21
Number of Products by Stage and Top 10 Targets, H2 2016 21
Number of Products by Mechanism of Actions, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Molecule Types, H2 2016 27

Companies Mentioned:

Foamix Pharmaceuticals Ltd
Laboratories Ojer Pharma SL
Lytix Biopharma AS
Toyama Chemical Co Ltd

License Types:

**Single User License (PDF)**

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Site License (PDF)**

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

**Global License (PDF)**

- This license allows for use of a publication by unlimited users within the purchasing organization.
e.g. all employees of a single company.

- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.

- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL: https://www.marketresearchreports.com/global-markets-direct/impetigo-pipeline-review-h2-2016

Links